Evidence map›Paper›PMID 34361810›Full record

ArticleMolecules (Basel, Switzerland)2021

Antimicrobial Peptide Modifications against Clinically Isolated Antibiotic-Resistant

Suthee Mangmee, Onrapak Reamtong, Thareerat Kalambaheti, Sittiruk Roytrakul, Piengchan Sonthayanon

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Antibiotic Alternatives and Next-Generation Therapeutics forAntibiotics (Basel, Switzerland) · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Suthee MangmeeDepartment of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand.ORCID 0000-0002-0989-6857
Onrapak ReamtongDepartment of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand.
Thareerat KalambahetiDepartment of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand.
Sittiruk RoytrakulFunctional Ingredients and Food Innovation Research Group, National Center for Genetic Engineering and Biotechnology, Pathumthani 12120, Thailand.ORCID 0000-0003-3696-8390
Piengchan SonthayanonDepartment of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand.ORCID 0000-0001-8164-3523

Funding

Deutscher Akademischer Austauschdienst program number 57433478/reference number 91714095Thailand Science Research and Innovation PHD60I0037Thailand Science Research and Innovation RDG61I0004
6 · The paper itself

Abstract

Antimicrobial peptides are promising molecules to address the global antibiotic resistance problem, however, optimization to achieve favorable potency and safety is required. Here, a peptide-template modification approach was employed to design physicochemical variants based on net charge, hydrophobicity, enantiomer, and terminal group. All variants of the scorpion venom peptide BmKn-2 with amphipathic α-helical cationic structure exhibited an increased antibacterial potency when evaluated against multidrug-resistant

Indexed as

AnimalsAnti-Bacterial AgentsAnti-Infective AgentsAntimicrobial Cationic PeptidesBiofilmsDrug Resistance, BacterialErythrocytesHemolysisMicrobial Sensitivity TestsPore Forming Cytotoxic ProteinsSalmonellaScorpion VenomsSheepStructure-Activity RelationshipAnti-Bacterial AgentsAnti-Infective AgentsAntimicrobial Cationic PeptidesPore Forming Cytotoxic ProteinsScorpion Venomsantimicrobial peptidebactericidal agentbiofilm inhibition and eradicationhemolytic activitymultidrug-resistantpeptide designstructure-activity relationship

Identifiers

PMID34361810
PMCPMC8348142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.